晚期非小细胞肺癌靶向治疗疗效预测标志物临床研究进展

Clinical research on prediction marker of efficacy in advanced non-small cell lung cancer

当前晚期非小细胞肺癌的发展趋势是个体化治疗，个体化治疗的关键是根据生物学标志物和临床标志物来制定不同的治疗方案，目前靶向治疗药物的生物学标志物包括EGFR蛋白表达、EGFR突变、EGFR基因拷贝、k-ras突变、EML4-ALK基因融合、e-met基因等，临床标志物包括皮疹及病理学类型。

Individualized therapy is the current trend of treatment in advanced non-small cell lung cancer, the key of individualized therapy is to administrer different treatment options through different biological markers or clinical markers. Currently, biological markers include EGFR protein expression, EGFR mutations, EGFR gene copy, k-ras mutation, EML4-ALK gene fusion, C-MET gene. Clinical markers include rash, pathological types, etc. This article will give a review about those biomarkers.